State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, School of Life Sciences, Xiamen University, Xiamen 361102, P.R. China; National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, Xiamen 361102, P.R. China.
Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Institute of Infectious Diseases and Biosecurity, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Cell Rep Methods. 2024 Sep 16;4(9):100856. doi: 10.1016/j.crmeth.2024.100856. Epub 2024 Sep 6.
The ongoing co-circulation of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains necessitates advanced methods such as high-throughput multiplex pseudovirus systems for evaluating immune responses to different variants, crucial for developing updated vaccines and neutralizing antibodies (nAbs). We have developed a quadri-fluorescence (qFluo) pseudovirus platform by four fluorescent reporters with different spectra, allowing simultaneous measurement of the nAbs against four variants in a single test. qFluo shows high concordance with the classical single-reporter assay when testing monoclonal antibodies and human plasma. Utilizing qFluo, we assessed the immunogenicities of the spike of BA.5, BQ.1.1, XBB.1.5, and CH.1.1 in hamsters. An analysis of cross-neutralization against 51 variants demonstrated superior protective immunity from XBB.1.5, especially against prevalent strains such as "FLip" and JN.1, compared to BA.5. Our finding partially fills the knowledge gap concerning the immunogenic efficacy of the XBB.1.5 vaccine against current dominant variants, being instrumental in vaccine-strain decisions and insight into the evolutionary path of SARS-CoV-2.
多种严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 株的持续共同循环需要先进的方法,如高通量多重假病毒系统,以评估针对不同变体的免疫反应,这对于开发更新的疫苗和中和抗体 (nAb) 至关重要。我们通过具有不同光谱的四个荧光报告基因开发了一个四荧光 (qFluo) 假病毒平台,允许在单次测试中同时测量针对四种变体的 nAb。qFluo 在测试单克隆抗体和人血浆时与经典的单报告基因检测具有高度一致性。利用 qFluo,我们评估了 BA.5、BQ.1.1、XBB.1.5 和 CH.1.1 刺突在仓鼠中的免疫原性。对 51 种变体的交叉中和分析表明,与 BA.5 相比,XBB.1.5 特别是对“FLip”和 JN.1 等流行株具有更好的保护免疫力。我们的发现部分填补了关于 XBB.1.5 疫苗对当前主要变体的免疫效力的知识空白,有助于疫苗株的决策,并深入了解 SARS-CoV-2 的进化路径。